智翔金泰：泰利奇拜单抗注射液成人季节性过敏性鼻炎适应症上市申请获得受理

Core Viewpoint - The company, Zhixiang Jintai, has achieved a significant milestone with its drug, GR1802 injection, for the treatment of adult seasonal allergic rhinitis, successfully reaching the primary endpoint in Phase III clinical trials and has submitted a new drug application to the National Medical Products Administration (NMPA) [1] Group 1 - GR1802 injection is a fully humanized monoclonal antibody targeting IL-4Rα, designed to inhibit Th2-type inflammatory responses by blocking the binding of IL-4 and IL-13 to IL-4Rα [1] - The new drug application for GR1802 injection for moderate to severe atopic dermatitis in adults was accepted in September 2025, indicating ongoing development in this area [1] - Multiple indications for GR1802 injection are currently in clinical trial stages, including chronic rhinosinusitis with nasal polyps and chronic spontaneous urticaria in Phase III, and asthma in Phase II [1] Group 2 - As of the announcement date, only two other drugs targeting the same pathway have been approved for marketing in China, highlighting the competitive landscape for GR1802 injection [2]